That is great news that they are going back to Dr Robert...

That is great news that they are going back to Dr Robert Nagourney . His ex vivo assay method has proven to be about 90% accurate . He has identified a pancreatic cancer treatment for breast cancer using his assay method that has become a standard treatment . Using his assays he treats sections of the cancer that have been removed from the patient with different chemos and combinations to give the patient the best chance of success .
If he has taken on the SBP002 , then he will be able to identify not only the cancers with the best chance of success for SBP002 , but also which combinations will work . Resulting in years of hit and miss eliminated .
He was the one that originally independently tested the original BEC compound . The 57% response was an average of all cancers tested , but if I recall correctly NSCLC response was closer to 75% response , with the old , less potent form of the drug . Also remember that the ex-vivo assays do not take into account the immune reaction , which kicks in some time after the drug has done its work . With the stronger drug and the more specific targeting , I believe we can expect higher responses than the 57% quoted .
Cheers